Eledon Pharmaceuticals Inc.
| NASDAQ: ELDN |
| Healthcare / Biotechnology / USA |
| 2.69 | 0 | 0.00 | Vol 46.08K | 1Y Perf -65.82% |
| Jun 24th, 2022 16:00 DELAYED |
| BID | 2.40 | ASK | 2.90 | ||
| Open | 2.70 | Previous Close | 2.69 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 25.40 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 844.24 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 6.75 | Earnings Rating | — | |
| Market Cap | 37.00M | Earnings Date | 11th Aug 2022 | |
| Alpha | -0.01 | Standard Deviation | 0.40 | |
| Beta | 1.93 |
Today's Price Range 2.662.89 | 52W Range 2.278.49 | 5 Year PE Ratio Range -0.6000-0.6000 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -1.82% | ||
| 1 Month | -13.50% | ||
| 3 Months | -31.03% | ||
| 6 Months | -41.90% | ||
| 1 Year | -65.82% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -23.96 | |||
ROE last 12 Months | -21.74 | |||
ROA (5Y Avg) | -8.19 | |||
ROA last 12 Months | -20.95 | |||
ROC (5Y Avg) | -57.67 | |||
ROC last 12 Months | -21.02 | |||
Return on invested Capital Q | -6.13 | |||
Return on invested Capital Y | -5.25 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.10 | ||||
| 0.24 | ||||
| - | ||||
| - | ||||
| -1.20 | ||||
| -2.17 | ||||
| 0.50 | ||||
| 11.36 | ||||
| -38 305 400.00 | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 25.90 | ||||
| 26.80 | ||||
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| Leverage Ratio | 1.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2022 | -0.67 | -0.69 | -2.99 |
| Q04 2021 | -0.83 | -0.59 | 28.92 |
| Q03 2021 | -0.67 | -0.66 | 1.49 |
| Q02 2021 | -0.58 | -0.50 | 13.79 |
| Q01 2021 | -0.37 | -0.57 | -54.05 |
| Q03 2020 | -1.64 | -3.91 | -138.41 |
| Q02 2020 | - | -2.70 | - |
| Q01 2020 | - | -8.45 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 11th Aug 2022 |
| Estimated EPS Next Report | -0.72 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 46.08K |
| Shares Outstanding | 13.76K |
| Shares Float | 11.41M |
| Trades Count | 247 |
| Dollar Volume | 126.81K |
| Avg. Volume | 78.22K |
| Avg. Weekly Volume | 68.14K |
| Avg. Monthly Volume | 112.47K |
| Avg. Quarterly Volume | 54.07K |
Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) stock closed at 2.69 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 46.08K shares and market capitalization of 37.00M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. Eledon Pharmaceuticals Inc. CEO is David-Alexandre C. Gros.
The one-year performance of Eledon Pharmaceuticals Inc. stock is -65.82%, while year-to-date (YTD) performance is -39%. ELDN stock has a five-year performance of %. Its 52-week range is between 2.27 and 8.49, which gives ELDN stock a 52-week price range ratio of 6.75%
Eledon Pharmaceuticals Inc. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 0.24, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -20.95%, a ROC of -21.02% and a ROE of -21.74%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Eledon Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.72 for the next earnings report. Eledon Pharmaceuticals Inc.’s next earnings report date is 11th Aug 2022.
The consensus rating of Wall Street analysts for Eledon Pharmaceuticals Inc. is Strong Buy (1), with a target price of $25.4, which is +844.24% compared to the current price. The earnings rating for Eledon Pharmaceuticals Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Eledon Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Eledon Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.91, ATR14 : 0.36, CCI20 : -87.45, Chaikin Money Flow : -0.28, MACD : -0.12, Money Flow Index : 64.14, ROC : -16.46, RSI : 42.40, STOCH (14,3) : 16.25, STOCH RSI : 0.60, UO : 41.92, Williams %R : -83.75), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Eledon Pharmaceuticals Inc. in the last 12-months were:
Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody.
CEO: David-Alexandre C. Gros
Telephone: +1 949 238-8090
Address: 19900 MacArthur Boulevard, Irvine 92612, CA, US
Number of employees: 10
TipRanks News for ELDN
Tue, 07 Jun 2022 13:55 GMT Analysts Are Bullish on Top Healthcare Stocks: Eledon Pharmaceuticals (ELDN), Treace Medical Concepts (TMCI)
- TipRanks. All rights reserved.Sat, 09 Apr 2022 03:15 GMT Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE), Eledon Pharmaceuticals (ELDN) and Nurix Therapeutics (NRIX)
- TipRanks. All rights reserved.Fri, 25 Mar 2022 15:55 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Eledon Pharmaceuticals (ELDN), Lantheus (LNTH) and Moderna (MRNA)
- TipRanks. All rights reserved.
